Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fate Therapeutics, Inc.

https://fatetherapeutics.com/

Latest From Fate Therapeutics, Inc.

ASCO: Presentations Showcase Possibilities Of Next-Generation Cell Therapies

An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.

ASCO ImmunoOncology

Fate’s Phase I NK Cell Therapy Sparks Optimism, But Longer Follow-Up Needed

While the data are early, they have also generated positive views toward the company’s pipeline ahead of an anticipated CAR-NK data announcement at its investor meeting.

ASCO ImmunoOncology

Could Outpatient Cell Therapies Provide Way Out Of Bundled Payment Trap?

Giving cell therapies as outpatient rather than inpatient treatments could be a way around the need for bundled payments, but it’s not universally applicable.

ASCO Biologics

Catching Up With Fate: Deal With CRISPR Brings Nkarta Up In NK Cell Race

The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.

Deals Research and Development Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Tfinity Therapeutics, Inc.
UsernamePublicRestriction

Register